Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if DMRA is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
25 top institutions tracked
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: neutral
Last trade: buy 16 days ago
Red flags: 0
101 filers reported a long position in DMRA for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| FMR LLC | $240.1M | 9.2M | +2.1% |
| Fairmount Funds Management LLC | $226.6M | 8.7M | Unchanged |
| Avoro Capital Advisors LLC | $98.4M | 3.8M | Unchanged |
| Venrock Adviser, LLC | $93.7M | 3.6M | Unchanged |
| BlackRock, Inc. | $82.2M | 3.2M | +1,321.6% |
| FCPM III SERVICES B.V. | $63.5M | 2.4M | Unchanged |
| RA CAPITAL MANAGEMENT, L.P. | $62.4M | 2.4M | 0% |
| VIKING GLOBAL INVESTORS LP | $60.1M | 2.3M | Unchanged |
| Jupiter Topco LLC | $59.3M | 2.3M | — |
| Remedium Capital Partners, LLC | $53.2M | 2M | Unchanged |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.